Transitioning From Cyclosporine to Alefacept in Psoriasis

• Status: Completed
• Trial end date: 2007-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to devise a safe and effective method for transitioning patients from cyclosporine to alefacept.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Medicine and Dentistry of New Jersey
• Collaborator: Biogen
• Treatments: Alefacept; Cyclosporine; Cyclosporins

Criteria

Inclusion Criteria

• Adult psoriasis patients (18 to 80 years old), who are well controlled on cyclosporine (Static PGA score of mild, minimal or clear) and who need or desire to stop cyclosporine and start alefacept.

Exclusion Criteria

• CD4 <400

• Active infection (other than trivial URI, etc.)

• History of AIDS or Hepatitis B, C

• Inability to understand consent or comply with study requirements

• Pregnancy or Lactation

• History of heart or liver disease